HDAC9 and lung cancer: -Increased the sub-G1 (apoptotic) fraction of cells through caspase-3 and -7 dependent pathways-Inhibited the invasive potential of LNM35, MCF-7/6, and MDA-MB231- 1833 cancer cells-Inhibited the HDAC activity-Potentiated the cytotoxicity of cisplatin in LNM35 cells-Decreased the growth of LNM35 tumor xenografts in athymic mice⇒ Luteolin, in combination with standard anticancer drugs such as cisplatin, may be a promising HDAC inhibitor for the treatment of lung cancer